AMAL Therapeutics to publish in vivo research outcomes in Frontiers in Immunology
Geneva, Switzerland, July 1, 2021 – AMAL Therapeutics announced today that the latest findings of its in vivo research team is on line on the Frontiers in Immunology website.
AMAL Therapeutics to publish R&D outcomes in Cancers
Geneva, Switzerland, February 17, 2021 – AMAL Therapeutics announced today that its recent research findings, in collaboration with Fox Chase Cancer Center, about a novel protein‐based vaccine against self‐antigen reducing the formation of sporadic colon adenomas in mice, is on line on the Cancers website.
Season Greetings
A very happy holiday season from the whole AMAL team, and a great start into 2021!
AMAL Therapeutics SA announces the appointment of Dr. Thomas Bogenrieder as Chief Clinical Officer
We are very happy to welcome Thomas Bogenrieder, MD, PhD, as Chief Clinical Officer of AMAL Therapeutics as of July 1, 2020. Thomas will join AMAL’s operations in Geneva.
Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform
Boehringer Ingelheim today announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its technology platform KISIMA.


You are now leaving our website

Using this link will let you leave a website of Amal Therapeutics or to a different domain under the control of Amal Therapeutics. In the event that the linked site is not under the control of Amal Therapeutics but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, Amal Therapeutics shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites.

This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by Amal Therapeutics of the site.

Target URL: